Navigation Links
Edison Issues Initiation on Quantum Genomics (ALQGC)

LONDON, November 29, 2016 /PRNewswire/ --

We are initiating coverage on Quantum Genomics, a biopharmaceutical company investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and heart failure with a completed and an ongoing Phase IIa study, respectively. This pathway has been implicated in patients with complicated hypertension including those who are resistant to other treatments (25%) and 52% of hypertensive African Americans. We initiate with a valuation of €172m.


We value Quantum Genomics at €172m or €20.51/share based on a risk-adjusted NPV. We value the two programmes at €79m and €80m, although this represents higher revenue potential ($2.1bn vs $1.3bn peak sales) and higher development cost for hypertension. We forecast that the company will require €20m in financing before it can out-license the programmes in 2019 after completing Phase IIb studies.

Click here to view the full report.

Continue Reading
Edison Logo
Edison Logo

All reports published by Edison are available to download free of charge from its website

About Edison: Edison is an international equity research firm with a team of over 70 analysts, investment and roadshow professionals and works with both large and smaller capitalised companies, blue chip institutional investors, wealth managers, private equity and corporate finance houses to support their capital markets activity. Edison provides services to more than 420 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact: 

Maxim Jacobs
Edison Investment Research

Nathaniel Calloway
Edison Investment Research

Contact details: Learn more at and connect with Edison on:  


SOURCE Edison Investment Research
Copyright©2016 PR Newswire.
All rights reserved

Related biology technology :

1. CellHealth Institute is Named 2013 Edison Award Winner
2. Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma
3. Edison expands international biotechnology presence with launch of full coverage of Athersys
4. Edison Expands its European Pharmaceutical Coverage by Initiating on MagForce
5. Edison beginnt Coverage von Magforce, einem deutschen Unternehmen für nanotechnologische Krebsbekämpfung
6. Cardio3 BioSciences, a European biopharmaceutical company, now covered by Edison Investment Research
7. Edison Initiates Coverage on Relmada Therapeutics
8. AnthroTronix Named Edison Awards Finalist for Brain Health Assessment Tool
9. Edison Initiates Coverage on Novogen
10. Edison Initiates Coverage on PDL BioPharma
11. Industry Leading Life Science Career Fair in Edison, NJ Attracts Top Employers
Post Your Comments:
(Date:10/9/2017)... ... October 09, 2017 , ... ... October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System ... standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography ...
(Date:10/7/2017)... Seattle, WA (PRWEB) , ... ... ... the industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome ... the ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C ...
(Date:10/6/2017)... ... 06, 2017 , ... The HealthTech Venture Network (HTVN) is ... fourth annual Conference where founders, investors, innovative practitioners and collaborators are invited to ... showcasing early stage digital health and med tech companies. , This day-long event ...
(Date:10/5/2017)... CA (PRWEB) , ... October 05, 2017 , ... ... engineers, and scientists from around the world, is giving back to cancer research with ... in October. , Now through October 31, shoppers can use promo code PinkRibbon ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
Breaking Biology News(10 mins):